entertainment -WSS

entertainment

author：explore 2025-09-30 19:25:22 - browse：48

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Stem cell biologist probes earliest stages of human development

WSS

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Colonoscopy prep: Liquid

SCOTUS questions limit to govt efforts to fight misinformation

Orchard's therapy for neuron disease in children wins FDA approval

Virtual Event: March of the Biosimilars

Biden's 'march

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Harvard's David Sinclair gets blowback over aging

Guidelines to prevent youth baseball injuries need more muscle

Ozempic has benefits for kidney disease as well as diabetes

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Bluebird, CVS, Contineum

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Sports medicine is finally prioritizing gender equality

Longer MASH drug regimen improved liver, Akero study finds

focus

Readout Newsletter: Bluebird, CVS, Contineum

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Positive childhood experiences can help future health

Fetal cell organoids grown from amniotic fluid, study finds

Neuroscience’s long legacy of racism

focus

explore

leisure time

hotspot